{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-041708","form_type":"8-K","ticker":null,"cik":"0001845459","company_name":"NKGen Biotech, Inc.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.739186+00:00","generated_at":"2026-06-02T04:09:39.019607+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NKGen Biotech raises $1M gross from convertible notes; warrants at $2.00","bullets":["Total gross proceeds of $1M from three convertible promissory notes to Meteora ($200k), Alpha ($500k), and AJB ($300k).","Aggregate principal amount $1.21M; notes mature in 12 months; convertible at $2.00 per share.","Warrants issued to purchase up to 1.1M shares at $2.00 per share for five years.","Alpha and AJB have options to require additional notes and warrants worth up to $2.96M and 2.64M shares.","Notes include original issue discounts; Meteora Note bears 12% interest; others zero coupon."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-041708","json":"https://secwatch.observer/filing/0001213900-24-041708.json","markdown":"https://secwatch.observer/filing/0001213900-24-041708.md","text":"https://secwatch.observer/filing/0001213900-24-041708.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845459/000121390024041708/0001213900-24-041708-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845459/000121390024041708/ea0205751-8k_nkgenbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:09:39.019607+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0aa56e1b6bae11f29c16bfbf59cdb119dfe796e1","claim":"NKGen Biotech, Inc. entered into Meteora Purchase Agreement with Meteora Select Trading Opportunities Master, LP, Meteora Capital Partners, LP and Meteora Strategic Captial, LLC (collectively, \"Meteora\") valued at $220,000 (effective 2024-05-07).","evidence_excerpt":"On May 7, 2024, the Company issued a 12% promissory note (the “ Meteora Note ”) in the principal amount of $220,000, pursuant to a Securities Purchase Agreement (the “ Meteora Purchase Agreement ”), by and among Meteora Select Trading Opportunities Master, LP, Meteora Capital Partners, LP and Meteora Strategic Captial, LLC (collectively, “ Meteora ”) and the Company.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390024041708/0001213900-24-041708-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Meteora Select Trading Opportunities Master, LP, Meteora Capital Partners, LP and Meteora Strategic Captial, LLC (collectively, \"Meteora\")"},{"label":"Value","value":"$220,000"},{"label":"Effective","value":"2024-05-07"}],"fact_type":"material_agreement"},{"claim_id":"5e16ac1f4b91d81b65e83a577103f6d62dbe27c6","claim":"NKGen Biotech, Inc. entered into AJB Purchase Agreement with AJB Capital Investments LLC (\"AJB\") valued at $369,600 (effective 2024-05-09).","evidence_excerpt":"On May 9, 2024, the Company entered into to a Securities Purchase Agreement (the “ AJB Purchase Agreement ”), by and between AJB Capital Investments LLC (“ AJB ”) and the Company.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390024041708/0001213900-24-041708-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"AJB Capital Investments LLC (\"AJB\")"},{"label":"Value","value":"$369,600"},{"label":"Effective","value":"2024-05-09"}],"fact_type":"material_agreement"},{"claim_id":"e8bded369c358657ddfd6e0b9d49ddc077cb0b11","claim":"NKGen Biotech, Inc. entered into Alpha Purchase Agreement with Generating Apha Ltd. (\"Alpha\") valued at $616,000 (effective 2024-05-07).","evidence_excerpt":"On May 7, 2024, the Company issued a zero coupon promissory note (the “ Alpha Note ”) in the principal amount of $616,000, pursuant to a Securities Purchase Agreement (the “ Alpha Purchase Agreement ”), by and between Generating Apha Ltd. (“ Alpha ”) and the Company.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390024041708/0001213900-24-041708-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Generating Apha Ltd. (\"Alpha\")"},{"label":"Value","value":"$616,000"},{"label":"Effective","value":"2024-05-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}